Talphera (TLPH) Preferred Stock Liabilities (2010 - 2022)
Talphera's (TLPH) quarterly Preferred Stock Liabilities came in at $315000.0 in Q3 2022, down 99.44% quarter-over-quarter from $55.9 million in Q4 2010.
Talphera (TLPH) Preferred Stock Liabilities (2010 - 2022) Analysis & Trends
Talphera's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $315000.0 for Q3 2022.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $315000.0 in Q3 2022; TTM through Sep 2022 was $315000.0, a N/A change from a year earlier, with the FY2010 full-year figure at $55.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities declined to $315000.0 in Q3 2022 per TLPH's latest filing, from $55.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $315000.0 in Q3 2022 and bottomed at $315000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 315,000.00 |
| Dec 31, 2010 | 55.94 Mn |